Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

Jan Styczynski; Lidia Gil; Gloria Tridello; Per Ljungman; J. Peter Donnelly; Walter Van Der Velden; Hamdy Omar; Rodrigo Martino; Constantijn Halkes; Maura Faraci; Koen Theunissen; Krzysztof Kalwak; Petr Hubacek; Simona Sica; Chiara Nozzoli; Franca Fagioli; Susanne Matthes; Miguel A. Diaz; Maddalena Migliavacca; Adriana Balduzzi; Agnieszka Tomaszewska; Rafael De La Camara; Anja Van Biezen; Jennifer Hoek; Simona Iacobelli; Hermann Einsele; Simone Cesaro

doi:10.1093/cid/cit391

Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

Jan Styczynski, Lidia Gil, Gloria Tridello, Per Ljungman, J. Peter Donnelly, Walter Van Der Velden, Hamdy Omar, Rodrigo Martino, Constantijn Halkes, Maura Faraci, Koen Theunissen, Krzysztof Kalwak, Petr Hubacek, Simona Sica, Chiara Nozzoli, Franca Fagioli, Susanne Matthes, Miguel A. Diaz, Maddalena Migliavacca, Adriana BalduzziAgnieszka Tomaszewska, Rafael De La Camara, Anja Van Biezen, Jennifer Hoek, Simona Iacobelli, Hermann Einsele, Simone Cesaro

Risultato della ricerca: Contributo in rivista › Articolo in rivista

116 Citazioni (Scopus)

Abstract

The objective of this analysis was to investigate prognostic factors that influence the outcome of Epstein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after a rituximab-based treatment in the allogeneic hematopoietic stem cell transplant (HSCT) setting.

Lingua originale	English
pagine (da-a)	794-802
Numero di pagine	9
Rivista	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume	57
DOI	https://doi.org/10.1093/cid/cit391
Stato di pubblicazione	Pubblicato - 2013

Keywords

Epstein-Barr virus
hematopoietic stem cell transplantation
post-transplant lymphoproliferative disorder
prognostic model
risk factors

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1093/cid/cit391

Altri file e collegamenti

Link a IRIS PubliCatt

Fingerprint

Entra nei temi di ricerca di 'Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation'. Insieme formano una fingerprint unica.

Cita questo

Styczynski, J., Gil, L., Tridello, G., Ljungman, P., Donnelly, J. P., Van Der Velden, W., Omar, H., Martino, R., Halkes, C., Faraci, M., Theunissen, K., Kalwak, K., Hubacek, P., Sica, S., Nozzoli, C., Fagioli, F., Matthes, S., Diaz, M. A., Migliavacca, M., ... Cesaro, S. (2013). Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 57, 794-802. https://doi.org/10.1093/cid/cit391

Styczynski, Jan ; Gil, Lidia ; Tridello, Gloria et al. / Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013 ; Vol. 57. pagg. 794-802.

@article{73efc2e84e8c430bbf9e17ede29d34f5,

title = "Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation",

abstract = " The objective of this analysis was to investigate prognostic factors that influence the outcome of Epstein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after a rituximab-based treatment in the allogeneic hematopoietic stem cell transplant (HSCT) setting.",

keywords = "Epstein-Barr virus, hematopoietic stem cell transplantation, post-transplant lymphoproliferative disorder, prognostic model, risk factors, Epstein-Barr virus, hematopoietic stem cell transplantation, post-transplant lymphoproliferative disorder, prognostic model, risk factors",

author = "Jan Styczynski and Lidia Gil and Gloria Tridello and Per Ljungman and Donnelly, {J. Peter} and {Van Der Velden}, Walter and Hamdy Omar and Rodrigo Martino and Constantijn Halkes and Maura Faraci and Koen Theunissen and Krzysztof Kalwak and Petr Hubacek and Simona Sica and Chiara Nozzoli and Franca Fagioli and Susanne Matthes and Diaz, {Miguel A.} and Maddalena Migliavacca and Adriana Balduzzi and Agnieszka Tomaszewska and Camara, {Rafael De La} and {Van Biezen}, Anja and Jennifer Hoek and Simona Iacobelli and Hermann Einsele and Simone Cesaro",

year = "2013",

doi = "10.1093/cid/cit391",

language = "English",

volume = "57",

pages = "794--802",

journal = "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America",

}

Styczynski, J, Gil, L, Tridello, G, Ljungman, P, Donnelly, JP, Van Der Velden, W, Omar, H, Martino, R, Halkes, C, Faraci, M, Theunissen, K, Kalwak, K, Hubacek, P, Sica, S, Nozzoli, C, Fagioli, F, Matthes, S, Diaz, MA, Migliavacca, M, Balduzzi, A, Tomaszewska, A, Camara, RDL, Van Biezen, A, Hoek, J, Iacobelli, S, Einsele, H & Cesaro, S 2013, 'Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 57, pagg. 794-802. https://doi.org/10.1093/cid/cit391

Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. / Styczynski, Jan; Gil, Lidia; Tridello, Gloria et al.
In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 57, 2013, pag. 794-802.

Risultato della ricerca: Contributo in rivista › Articolo in rivista

TY - JOUR

T1 - Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

AU - Styczynski, Jan

AU - Gil, Lidia

AU - Tridello, Gloria

AU - Ljungman, Per

AU - Donnelly, J. Peter

AU - Van Der Velden, Walter

AU - Omar, Hamdy

AU - Martino, Rodrigo

AU - Halkes, Constantijn

AU - Faraci, Maura

AU - Theunissen, Koen

AU - Kalwak, Krzysztof

AU - Hubacek, Petr

AU - Sica, Simona

AU - Nozzoli, Chiara

AU - Fagioli, Franca

AU - Matthes, Susanne

AU - Diaz, Miguel A.

AU - Migliavacca, Maddalena

AU - Balduzzi, Adriana

AU - Tomaszewska, Agnieszka

AU - Camara, Rafael De La

AU - Van Biezen, Anja

AU - Hoek, Jennifer

AU - Iacobelli, Simona

AU - Einsele, Hermann

AU - Cesaro, Simone

PY - 2013

Y1 - 2013

N2 - The objective of this analysis was to investigate prognostic factors that influence the outcome of Epstein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after a rituximab-based treatment in the allogeneic hematopoietic stem cell transplant (HSCT) setting.

AB - The objective of this analysis was to investigate prognostic factors that influence the outcome of Epstein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after a rituximab-based treatment in the allogeneic hematopoietic stem cell transplant (HSCT) setting.

KW - Epstein-Barr virus

KW - hematopoietic stem cell transplantation

KW - post-transplant lymphoproliferative disorder

KW - prognostic model

KW - risk factors

KW - Epstein-Barr virus

KW - hematopoietic stem cell transplantation

KW - post-transplant lymphoproliferative disorder

KW - prognostic model

KW - risk factors

UR - http://hdl.handle.net/10807/50962

U2 - 10.1093/cid/cit391

DO - 10.1093/cid/cit391

M3 - Article

VL - 57

SP - 794

EP - 802

JO - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

ER -

Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, Van Der Velden W et al. Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013;57:794-802. doi: 10.1093/cid/cit391